Diabetes treatments shown to lower heart complications in hospital and genetic studies

Researchers at the Instituto de Investigación Sanitaria y Biomédica de Alicante (Isabial) evaluated nearly 1,000 hospitalized type‑2 diabetes patients using the Endocare protocol, which combines insulin with oral agents such as SGLT2 inhibitors and GLP‑1 agonists. The observational study reported a 50 % reduction in clinically relevant hypoglycaemia, better glucose control and shorter hospital stays.

A separate study by Harvard, Brigham and Women’s Hospital and MIT analysed more than 12,500 trial participants and identified 121 carriers of genetic variants linked to cardiomyopathy. Treatment with the SGLT2 inhibitor dapagliflozin lowered the risk of heart‑failure hospitalisation by up to 80 % in this high‑risk group and by 32 % in others, highlighting the drug’s preventive potential for cardiac disease in diabetes patients.